The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Alosetron, a 5‐HT 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers
Open accessAbstract
Background: Alosetron is a potent and selective 5‐HT 3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non‐constipated irritable bowel syndrome. Aims: To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). Subjects: Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. Methods: Both studies were randomized, double‐blind, placebo‐controlled with a two‐way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio‐opaque markers; small bowel transit was determined from rise in breath hydrogen after a meal; and colonic transit and segmental transit were evaluated from abdominal X‐ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. Results: Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients ( P =0.128), which was confirmed in controls ( P =0.047). Conclusion: Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non‐constipated irritable bowel syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Drugs acting as antagonists at the 5-HT 3 receptor are also licensed for IBS-D. These include alosetron and ramosetron, which slow gastrointestinal transit, reduce visceral hypersensitivity and alter rectal compliance. [231][232][233]”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [231]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“5-HT3 antagonists and eluxadoline slow gastrointestinal transit and reduce visceral hypersensitivity”
From Irritable bowel syndrome (2020) · cites this paper as [119]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“5-HT3 antagonists and eluxadoline slow gastrointestinal transit and reduce visceral hypersensitivity”
From Irritable bowel syndrome (2020) · cites this paper as [119]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Simplified assessment of segmental colonic transit
Metcalf, A. M., Phillips, S. F., Zinsmeister, A. R., MacCarty, R. L., Beart, R. W., & Wolff, B. G. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90837-7 · Cited by 928
15 Design and Analysis of Cross-Over Trials
Kenward, M. G., & Jones, B. C. (2007) · Handbook of statistics · doi:10.1016/s0169-7161(07)27015-4 · Cited by 873
A new method for studying gut transit times using radioopaque markers
Hinton, J., Lennard‐Jones, J. E., & Young, A. C. (1969) · Gut · doi:10.1136/gut.10.10.842 · Cited by 838
Bowel Patterns Among Subjects Not Seeking g Health Care
Drossman, D. A., Sandler, R. S., McKee, D. C., & Lovitz, A. J. (1982) · Gastroenterology · doi:10.1016/s0016-5085(82)80186-8 · Cited by 711
Design and Analysis of Cross-Over Trials
Jones, B. C., & Kenward, M. G. (1989) · Chapman & Hall/CRC eBooks · doi:10.4324/9780203009277 · Cited by 694
Production and Excretion of Hydrogen Gas in Man
Levitt, M. D. (1969) · New England Journal of Medicine · doi:10.1056/nejm196907172810303 · Cited by 586
Koch, G. G. (1972) · Biometrics · doi:10.2307/2556170 · Cited by 465
Symptoms of irritable bowel syndrome in a British urban community: Consulters and nonconsulters
Heaton, K. W., O'Donnell, L. J. D., Braddon, F., Mountford, R. A., Hughes, A., & Cripps, P. J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90320-x · Cited by 382
Cann, P. A., Read, N. W., Brown, C., Hobson, N., & Holdsworth, C. D. (1983) · Gut · doi:10.1136/gut.24.5.405 · Cited by 365
Camilleri, Mayer, Drossman, Heath, Dukes, McSorley, D., Kong, Mangel, A. W., & Northcutt (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00610.x · Cited by 365
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
Delvaux, M., Louvel, D., Mamet, J. ‐., Campos‐Oriola, R., & Frexinos, J. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00375.x · Cited by 236
Review article: the role of inflammation in the pathogenesis of gastric cancer
Ernst, P. B. (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00003.x · Cited by 219
Prior, A., & Read, N. W. (1993) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1993.tb00087.x · Cited by 178
Talley, N. J. (1992) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1992.tb00050.x · Cited by 168
Bardhan, Bodemar, Geldof, Schütz, Heath, Mills, & Jacques (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00684.x · Cited by 158
Visceral perception in irritable bowel syndrome
Zighelboim, J., Talley, N. J., Phillips, S. F., Harmsen, W. S., & Zinsmeister, A. R. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02064986 · Cited by 152
Review article: an integrated approach to the irritable bowel syndrome
Drossman, D. A. (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.0130s2003.x · Cited by 130
Serotonergic mediation of postprandial colonic tonic and phasic responses in humans.
von der Ohe, M. R., Hanson, R. B., & Camilleri, M. (1994) · Gut · doi:10.1136/gut.35.4.536 · Cited by 128
GORE, S., Gilmore, I. T., Haigh, C. G., Brownless, S. M., Stockdale, H. R., & Morris, A. I. (1990) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1990.tb00458.x · Cited by 109
Steadman, C., Talley, N. J., Phillips, S. F., & Zinsmeister, A. (1992) · Mayo Clinic proceedings · doi:10.1016/s0025-6196(12)60797-6 · Cited by 108
Maxton, D. G., Morris, J. A., & Whorwell, P. J. (1996) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1996.30172000.x · Cited by 96
GR 38032F (Ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man
Talley, N., Phillips, S., Haddad, A., Miller, L., Twomey, C. K., Zinsmeister, A., Maccarty, R., & Ciociola, A. (1990) · Digestive Diseases and Sciences · doi:10.1007/bf01536922 · Cited by 95
Goldberg, P. A., Kamm, M. A., Setti-Carraro, P., van der Sijp, J. R. M., & Roth, C. (2009) · Digestion · doi:10.1159/000201377 · Cited by 94
Humphrey, P. P. A., Bountra, C., Clayton, N. M., & Kozlowski, K. (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00003.x-i2 · Cited by 94
A 5HT3 antagonist corrects the postprandial colonic hypertonie response in carcinoid diarrhea
von der Ohe, M. R., Camilleri, M., & Kvols, L. K. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90008-6 · Cited by 70
Bearcroft, C. P., Andrè, E., & Farthing, M. J. G. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.d01-1389.x · Cited by 64
[Epidemiology of intestinal functional disorders in an apparently healthy population].
Bommelaer, G., Rouch, M., Dapoigny, M. C., Pais, D., Loisy, P., Gualino, M., & Tournut, R. (1986) · PubMed · Cited by 50
Clayton, Sargent, BUTLER, GALE, Maxwell, Hunt, J. A., Barrett, CAMBRIDGE, BOUNTRA, & HUMPHREY (1999) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.1999.00148.x · Cited by 40
Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine.
Schwörer, H., Münke, H., Stöckmann, F., & Ramadori, G. P. (1995) · PubMed · Cited by 32
Serotonin Antagonists Inhibit Sennoside-lnduced Fluid Secretion and Diarrhea
Beubler, E., & Schirgi‐Degen, A. (2008) · Pharmacology · doi:10.1159/000139844 · Cited by 31
Ketanserin and Granisetron Reduce Cholera Toxin-Induced Hypersecretion in Pig Jejunum
Hansen, M. B., & Skadhauge, E. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409094862 · Cited by 20
Sensory dysfunction and the irritable bowel syndrome
Houghton, L. A. (1999) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.1999.0036 · Cited by 17
Treatment of female IBS patients with alosetron, a potent and selective 5HT3-receptor antagonist
Mangel, A. W., Camilleri, M., Chey, W., Hamm, L. R., Harding, J., Lawler, C. A., Dukes, G., McSorley, D., Alharazy, S. M., Heath, A., et al. (1999) · Gastroenterology · Cited by 9
Research works printed but not linked: 3
- MayerEA MunakataJ MertzH LemboT BernsteinCN.Visceral hyperalgesia and irritable bowel syndrome. In: Gebhert GF ed. Visceral Pain Progress in Pain Research and Management Vol 5. Seattle USA: IASP Press 1995: 429–68.
- Thompson WG, 1992, Functional bowel disease and functional abdominal pain. Working team report, Gastroenterol Int, 5, 75
- Lubke HJ, 1988, 5‐HT3 receptors have minimal effects on normal gut function, Gastroenterology, 94, A271
Cited by
Sorted by citations
Guidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., et al. (2007) · Gut · doi:10.1136/gut.2007.119446 · Cited by 818
Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31548-8 · Cited by 818
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 664
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine
Saha, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6759 · Cited by 500
Metadata
- Authors
- Houghton, Foster, & Whorwell
- Affiliations
- Manchester University NHS Foundation Trust (GB)
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2000-06
- Volume
- 14
- Issue
- 6
- Pages
- 775-782
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2049197933
- Cited by
- 132
- References
- 34
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 2 · 2019: 5 · 2018: 3 · 2016: 4 · 2015: 3 · 2014: 8 · 2013: 2 · 2012: 3
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Keywords
- alosetron, 5-HT3 receptor antagonists, irritable bowel syndrome, colonic transit, whole gut transit, small intestinal transit, radio-opaque markers, breath hydrogen, abdominal radiography
- MeSH terms
- Adult, Carbolines, Colon, Colonic Diseases, Functional, Double-Blind Method, Female, Gastrointestinal Transit, Humans, Intestine, Small, Male, Middle Aged, Serotonin Antagonists, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
